Adalimumab and Pneumococcal Conjugate Vaccine (7-Valent)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

If you are currently being treated or have recently been treated with adalimumab, you should let your doctor know before receiving pneumococcal 7-valent conjugate vaccine. Depending on the dose and length of time you have been on adalimumab, you may have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of adalimumab therapy. If you have recently been vaccinated with pneumococcal 7-valent conjugate vaccine, your doctor may choose to postpone treatment with adalimumab for a couple of weeks. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than 10 mg/day or 1 mg/kg/day of prednisone or equivalent for more than 2 weeks), or long-term topical or inhaled corticosteroids.

MANAGEMENT: In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases. Local guidelines should be consulted. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities agree that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).

Adalimumab

Generic Name: adalimumab

Brand name: Humira, Humira Pen, Humira Pen Crohns/UlcerColit/HidraSuppur, Humira Pen Psoriasis/Uveitis Starter Package, Humira Pediatric, Humira Pediatric Crohn's Disease Starter Pack, Humira Pre-Filled Syringe, Humira Pen Psoriasis/Uveitis/Adol HidraSuppur Starter Pack, Humira Pen Crohns/Ulcer Colitis/Hidradenitis Suppurati StrPk

Synonyms: n.a.

What is Adalimumab?

Pneumococcal Conjugate Vaccine (7-Valent)

Generic Name: pneumococcal 7-valent vaccine

Brand name: Prevnar

Synonyms: n.a.

What is Pneumococcal Conjugate Vaccine (7-Valent)?